Company intelligence / Profile preview
Regel Therapeutics
Cambridge, Massachusetts, United Statesregeltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Regel Therapeutics is developing gene modulation therapies using a deactivated Cas system (dCas) that targets the epigenome without editing DNA. Their approach aims to restore normal gene expression in disease-affected cells. The company has multiple programs in preclinical development.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Gene therapyGene modulation therapyAAV based gene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Strategic industry partner for muscle gene targets
Beyond the preview
Go deeper on Regel Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regel Therapeutics.